Role of peroxiredoxin i in rectal cancer and related to p53 status

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 3, 2010, Pages 868-878

  Chen, Miao Fen ^a,b   Lee, Kuan Der ^a,b   Yeh, Chung Hung ^b   Chen, Wen Cheng ^a,b   Huang, Wen Shih ^a,b   Chin, Chih Chien ^a,b   Lin, Paul Yang ^b   Wang, Jeng Yi ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

p53 status; Peroxiredoxin I; radiation; rectal cancer

Indexed keywords

ANIMAL EXPERIMENTS; CANCER TREATMENT; CLINICAL OUTCOME; DNA DAMAGES; IMMUNOCHEMICAL STAINING; IMMUNOHISTOCHEMICAL STAINING; NEOADJUVANT CHEMORADIOTHERAPY; NEOADJUVANT THERAPY; P53 STATUS; PEROXIREDOXIN I; PREDICTIVE CAPACITY; RECTAL CANCER; SCAVENGE REACTIVE OXYGEN SPECIES; TRANSFECTANTS; TREATMENT RESPONSE; TUMOR GROWTH; WILD TYPES;

BIOCHEMISTRY; DISEASES; OXYGEN; TUMORS;

RADIOTHERAPY;

PEROXIREDOXIN 1; PROTEIN P53; REACTIVE OXYGEN METABOLITE; ABELSON KINASE; PEROXIREDOXIN; TUMOR MARKER; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CARCINOGENESIS; CELL STRAIN HCT116; CELL STRAIN HT29; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION; RADIOSENSITIVITY; RECTUM CANCER; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; ADJUVANT THERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; CHEMISTRY; DRUG RESISTANCE; GENE SILENCING; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY; PROCEDURES; PROTEIN MICROARRAY; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; RECTAL NEOPLASMS; SURVIVAL; TREATMENT OUTCOME; TUMOR EMBOLISM; XENOGRAFT;

ANIMALS; CASE-CONTROL STUDIES; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; HCT116 CELLS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASTIC CELLS, CIRCULATING; PEROXIREDOXINS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-ABL; RADIATION TOLERANCE; REACTIVE OXYGEN SPECIES; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77957194152     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.05.025     Document Type: Article

References (36)

1. M. Mohiuddin, J. Marks, and G. Marks Management of rectal cancer: short- vs. long-course preoperative radiation Int J Radiat Oncol Biol Phys 72 2008 636 643
2. R. Sauer, H. Becker, and W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351) 2004 1731 1740
3. J.G. Kuremsky, J.E. Tepper, and H.L. McLeod Biomarkers for response to neoadjuvant chemoradiation for rectal cancer Int J Radiat Oncol Biol Phys 74 2009 673 688
4. B.D. Lawenda, K.M. Kelly, and E.J. Ladas Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 100 2008 773 783
5. H. Shau, A.T. Kim, and C.C. Hedrick Endogenous natural killer enhancing factor-B increases cellular resistance to oxidative stresses Free Radic Biol Med 22 1997 497 507
6. M.K. Cha, K.H. Suh, and I.H. Kim Overexpression of peroxiredoxin I and thioredoxin 1 in human breast carcinoma J Exp Clin Cancer Res 28 2009 93
7. J.H. Kim, P.N. Bogner, and S.H. Baek Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target Clin Cancer Res 14 2008 2326 2333
8. Y. Qi, J.F. Chiu, and L. Wang Comparative proteomic analysis of esophageal squamous cell carcinoma Proteomics 5 2005 2960 2971
9. B. Zhang, Y. Wang, and Y. Su Peroxiredoxins, a novel target in cancer radiotherapy Cancer Lett 286 2009 154 160
10. D. Ma, E. Warabi, and T. Yanagawa Peroxiredoxin I plays a protective role against cisplatin cytotoxicity through mitogen activated kinase signals Oral Oncol 45 2009 1037 1043
11. J. Cao, J. Schulte, and A. Knight Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity EMBO J 28 2009 1505 1517
12. D.P. Lane Cancer: p53, guardian of the genome Nature 358 1992 15 16
13. S. Macip, M. Igarashi, and P. Berggren Influence of induced reactive oxygen species in p53-mediated cell fate decisions Mol Cell Biol 23 2003 8576 8585
14. R.V. Sionov, and Y. Haupt The cellular response to p53: The decision between life and death Oncogene 18 1999 6145 6157
15. M.F. Chen, P.C. Keng, and H. Shau Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression Int J Radiat Oncol Biol Phys 64 2006 581 591
16. M.F. Chen, W.C. Chen, and C.T. Wu p53 Status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment Int J Radiat Oncol Biol Phys 66 2006 1461 1472
17. N.R. Rodrigues, A. Rowan, and M.E. Smith p53 Mutations in colorectal cancer Proc Natl Acad Sci USA 87 1990 7555 7559 (Pubitemid 20341755)
18. M.F. Chen, K.D. Lee, and M.S. Lu The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma J Mol Med 87 2009 307 320
19. J.Y. Wang, S.R. Lin, and D.C. Wu Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels Clin Cancer Res 13 2007 2406 2413
20. P.G. Komarov, E.A. Komarova, and R.V. Kondratov A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy Science 285 1999 1733 1737
21. E. Lopez-Crapez, F. Bibeau, and S. Thézenas p53 Status and response to radiotherapy in rectal cancer: A prospective multilevel analysis Br J Cancer 92 2005 2114 2121
22. S.T. Wen, and R.A. Van Etten The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity Genes Dev 11 1997 2456 2467
23. K. Bensaad, and K.H. Vousden Savior and slayer: The two faces of p53 Nat Med 11 2005 1278 1279
24. Y. Levav-Cohen, Z. Goldberg, and V. Zuckerman c-Abl as a modulator of p53 Biochem Biophys Res Commun 331 2005 737 749
25. L.H. Butterfield, A. Merino, and S.H. Golub From cytoprotection to tumor suppression: The multifactorial role of peroxiredoxins Antioxid Redox Signal 1 1999 385 402
26. C.A. Neumann, D.S. Krause, and C.V. Carman Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression Nature 424 2003 561 565
27. Y.J. Kim, J.Y. Ahn, and P. Liang Human Prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology Cancer Res 67 2007 546 554
28. A. Tulard, F. Hoffschir, and F.H. de Boisferon Persistent oxidative stress after ionizing radiation is involved in inherited radiosensitivity Free Radic Biol Med 35 2003 68 77
29. P. Okunieff, S. Swarts, and P. Keng Antioxidants reduce consequences of radiation exposure Adv Exp Med Biol 614 2008 165 178
30. J.M. Brown, and L.D. Attardi The role of apoptosis in cancer development and treatment response Nat Rev Cancer 5 2005 231 237
31. P.L. Olive, and J.P. Banath Phosphorylation of histone H2AX as a measure of radiosensitivity Int J Radiat Oncol Biol Phys 58 2004 331 335
32. S.K. Chen, M.H. Tsai, and J.J. Hwang Determination of 8-oxoguanine in individual cell nucleus of gamma-irradiated mammalian cells Radiat Res 155 2001 832 836
33. G. Achanta, and P. Huang Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents Cancer Res 64 2004 6233 6239
34. D.W. Meek The p53 response to DNA damage DNA Repair (Amst) 3 2004 1049 1056
35. R.A. Van Etten Cycling, stressed-out and nervous: Cellular functions of c-Abl Trends Cell Biol 9 1999 179 186
36. R.V. Sionov, E. Moallem, and M. Berger c-Abl neutralizes the inhibitory effect of Mdm2 on p53 J Biol Chem 274 1999 8371 8374